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a  b  s  t  r  a  c  t
The  natural  history  of Crohn’s  Disease  and  ulcerative  colitis  is  characterized  by repeated  episodes  of
inﬂammation  and  ulceration  of  the  bowel.  This  results  in  complications  implying  a worse  quality  of  life
and  signiﬁcant  healthcare  costs,  due  to  hospitalization,  surgery  and  an  escalation  of  therapy.
The  main  goal  of the  therapy  in  inﬂammatory  bowel  disease  is  to achieve  and  maintain  disease  remis-
sion,  with  an  improved  health-related  quality  of  life, less  hospitalization,  and  less  surgery.  The concept
of  remission  has  changed  in  the recent  years.  In  fact  the  concept  of  clinical  remission,  where  only  the
patients’  symptoms  are  in remission,  has  been  replaced  by  the  new  concept  of  deep  remission.  This
implies  not  only  sustained  clinical  remission  but  also  complete  mucosal  healing,  with  the  normalization
of  serological  activity  indexes.
Mucosal healing,  rarely  achieved  with  traditional  drugs,  can now  be  achieved  and  maintained  by  means
of  biological  drugs.  Current  evidence  suggests  that  the  achievement  of mucosal  healing  might  signiﬁcantly
change  the  natural  course  of  inﬂammatory  bowel  diseases  and  should  represent  an  objective  end  point
of  future  therapeutic  trials,  particularly  for  colonic  diseases.
© 2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica. Introduction
Inﬂammatory Bowel Disease (IBD), which includes both Crohn’s
isease (CD) and ulcerative colitis (UC), is a chronic idiopathic
nﬂammatory disorder affecting the gastrointestinal tract [1]. CD
nd UC affect more than 1 million people in the United States, with
housands of new diagnoses annually [2,3]. The natural history of
D and UC is characterized by repeated episodes of inﬂammation
nd ulceration of the bowel. This results in complications imply-
ng a worse quality of life and signiﬁcant healthcare costs, due to
ospitalization, surgery, and an escalation of therapy [4–6]. The
ain goal of the therapy in IBD is to achieve and maintain dis-
ase remission, with an improved health-related quality of life, less
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hospitalization, and less surgery [7]. The concept of remission has
changed in recent years. The concept of clinical remission, where
only the patients’ symptoms are in remission, has been replaced
by the new concept of deep remission. This implies not only a
sustained clinical remission but also a complete mucosal heal-
ing (MH), together with the normalization of serological activity
indexes (C-reactive protein, CRP). MH  is thought to be an impor-
tant prognostic feature for the efﬁcacy of treatment in IBD. MH
is assessed by endoscopy and is a component of intestinal heal-
ing, which determined by endoscopic healing, histological healing,
transmural healing and ﬁstula healing [8].
In this article we  review the clinical relevance and the clinical
implications of MH,  discussing its role in predicting the course of
IBD and its impact on decisions regarding medical strategies.
2.  Deﬁnition of MH
2.1.  Crohn’s Disease
Open access under CC BY-NC-ND license.Currently,  there is no validated gold standard deﬁnition of MH
in CD. Historically, endoscopy, rather than histology, has been the
focus of mucosal assessment in CD patients for several reasons.
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ecause of the segmental nature of CD, which can lead to sampling
rror when biopsies are performed, and the predilection of CD for
he ileum, histological scoring is inherently difﬁcult [9,10]. Also,
espite a number of histological activity indices have been devel-
ped, none of them has been prospectively validated. In addition,
ndoscopic assessment of disease activity in CD has been shown
o be better correlated with transmural inﬂammation and there-
ore to the actual severity of the disease [11]. Finally, there is a
aucity of data evaluating the impact of histological healing on
linical outcomes.
At  the moment, there are 2 validated indices for assessing endo-
copic activity in CD: CDEIS and SES-CD.
Both are too complex and cumbersome to be used routinely in
linical practice. Clinical trials examining endoscopic MH  as a sec-
ndary or even primary end point in CD have really only begun in
he last decade, corresponding to the era of both antitumor necro-
is factor alpha (anti-TNF) therapy and recognition of MH as a
otentially important treatment end point. In the 1990 the study
f the Groupe d’Etude Therapeutique des Affectiones Inﬂamma-
oires du Tube Digestif (GETAID) showed no signiﬁcant correlations
etween the clinical activity of the disease and the endoscopic
ctivity after treatment with steroids. In addition, they also showed
he low impact of endoscopic improvement in the long-term prog-
osis, and the ineffectiveness of steroid treatment intensiﬁcation
o obtain further endoscopic improvement [12]. With the use of
nﬂiximab, for the ﬁrst time a signiﬁcant correlation between the
ariations in the CDAI score and the CDEIS endoscopic score has
een demonstrated.
Regarding surgery for CD, Rutgeerts showed that the presence of
ucosal lesions with increasing severity predicts a high probability
f post-surgical recurrence [13]. Furthermore, Allez et al. showed
hat patients with active CD having deep and extensive ulcera-
ions, are, over a long period of time, at a greater increased relative
isk of undergoing colectomy compared to patients free of such
esions. The presence of deep ulcers and other severe endoscopic
esions was an independent risk factor for colectomy, together with
DAI > 288 and the absence of immunosuppressive treatment [14].
imilarly, in a Norwegian population-based cohort study, 11% of
D patients with MH  at 1 year needed surgical resection within 5
ears compared to 20% of patients without MH  [15].
Many different deﬁnitions of MH have been used over the years
nd, unfortunately, none of them has been validated or even uni-
ersally accepted. A recent expert consensus report deﬁned MH  in
D as the “restoration of normal mucosal appearance by endoscopy
f a previously inﬂamed region and the complete absence of ulcera-
ion and macroscopic and histological signs of inﬂammation” [16].
his rigorous combined endoscopic and histologic deﬁnition has
ot yet been applied to clinical trials, which have primarily used
ndoscopic indices to deﬁne MH  [10].
.2. Ulcerative colitis
Similarly  to CD, there is no validated goldstandard deﬁnition
f MH  in UC. Numerous endoscopic and histological indices have
een developed to measure disease activity in UC. All these indices
nclude overlapping endoscopic mucosal features, such as vascu-
arity, granularity, erythema, friability, bleeding, and ulceration.
owever, in many of these indices, clinically meaningful cut-off
cores for endoscopic remission or improvement have not been
eﬁned, and none has been prospectively validated. The devel-
pment of the new UCEIS was a collaborative effort involving
0 IBD specialists from 13 countries. It has been found that 3
ndoscopic features are the most discriminating: vascular pattern
score 1–3), bleeding (score 1–4), and erosions and ulcers (score
–4) [17]. UCEIS is currently undergoing independent validation.
ore recently, another index was developed and validated: ther Disease 45 (2013) 986– 991 987
UC  Colonoscopic Index of Severity (UCCIS), which provides repro-
ducible results in endoscopic scoring of patients with UC [18].
The  importance of achieving MH  in UC patients was  long ago
underscored by Wright and Truelove, who  showed that UC patients
not achieving MH under oral and rectal steroids relapsed more fre-
quently during a follow-up period of 1 year compared to patients
who did achieve it (40% vs. 18%, respectively) [19].
A  number of recent clinical trials of various medications for the
treatment of active UC have examined endoscopic MH  as a sec-
ondary end point but have used different deﬁnitions of MH.
Similar  to CD, there is much heterogeneity in the way MH  has
been deﬁned in UC, and none of these deﬁnitions has been val-
idated or universally accepted. The challenge lies in collectively
interpreting the results of studies that use different deﬁnitions of
MH.
3. Clinical implications of MH
3.1. Hospitalizations and surgery
The analysis of the signiﬁcance of MH  requires evaluation of the
therapeutic results in relation to the drivers of the direct costs of
IBD, mainly meaning hospitalization and surgery. Therefore, those
factors that may  affect the therapeutic results of these patients will
have signiﬁcant impacts in terms of reducing the social cost of this
disease [20]. Also, in the CHARM study it was  possible to demon-
strate a signiﬁcant reduction in the number of hospitalizations of
CD patients treated with adalimumab versus placebo. The relative
risk reduction is of 78% at 3 months, and 57% at 1 year in patients
treated with adalimumab compared to those treated with placebo
[21].
An observational cohort study of Norwegian IBD patients (IBSEN
cohort) showed that after a 1-year follow-up 38% of CD patients
and 50% of UC patients had evidence of MH;  after 1 year these
patients had fewer colectomies for UC than at 5 years of follow-
up (2% vs. 7%, p = 0.02); however, these ﬁndings refer to an earlier
cohort of patients followed up during the pre-biological treatment
era, when MH  was not yet considered a routine endpoint for clin-
ical trials [15]. Similarly, the study performed by Schnitzler et al.
[22], which is a “real-life” experience that highlights how MH  pre-
dicts long-term outcome of maintenance therapy with inﬂiximab
in Crohn’s Disease, showed that MH  was  associated with a signif-
icantly lower need for major abdominal surgery during long-term
follow-up (14.1% of patients with MH  needed major abdominal
surgery vs. 38.4% of patients without MH,  p = 0.0001).
With regard to the surgical setting in UC, a French study per-
formed in order to evaluate the value of colonoscopy for the
assessment of colonic ulcerations, enrolling 118 patients with
steroid-refractory UC, showed that the presence of severe endo-
scopic lesions was  an independent factor predictive of colectomy
[23]. Similarly, a prospective study by Solberg et al., performed to
evaluate the course of UC in a population-based inception cohort
and to identify prognostic risk factors, showed that patients who
presented with MH  within 1 year of diagnosis, independently of
the therapeutic regimen, had a signiﬁcantly lower risk of colectomy
[24].
3.2. Relapse rates after drug withdrawal
Among other clinical implications of MH,  we should consider
the relapse rate of the disease after drug withdrawal. The results
from the GETAID trials are contrasting. In this regard, Louis et al.
recently performed a study [25,26] to assess the risk of relapse
after discontinuation of inﬂiximab in patients on combined mainte-
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omplete MH  was among the factors strongly associated with a
ecreased risk of clinical relapse after inﬂiximab withdrawal; this
nding is in contrast with an older study by Lèmann (a random-
zed, double-blind, controlled, non-inferiority withdrawal trial in
D patients in long-term remission on azathioprine), in which the
resence of ulcerations at ileocolonoscopy, before discontinuation
f azathioprine, was not predictive of clinical relapse [27].
.3.  Quality of life
Similarly,  another end point that needs to be taken into account
s quality-of-life beneﬁt. A sub-study of the EXTEND trial (a
andomized, double-blind, placebo-controlled trial that was  per-
ormed to evaluate adalimumab for induction and maintenance of
H  in 135 adults with moderate to severe ileocolonic CD) showed,
t multivariate analysis, the signiﬁcant predictive effects of week
2 endoscopic assessment scores for quality-of-life outcomes at
eek 52 [28]. Interestingly, the EXTEND trial had MH  as primary
nd point of the study.
.4.  Colorectal cancer
Finally,  particularly for UC, it is important to consider that there
s a clear relationship between the grade and chronicity of the
nﬂammation in the colon and the risk of colorectal cancer. Indeed,
reater reduction of inﬂammation, as demonstrated by MH,  may
e associated with a decreased risk of colorectal cancer [29]. In
his regard, in a study of patients with long-standing UC who  were
ndergoing surveillance colonoscopy, in univariate analysis the
egree of colonoscopy and histologic inﬂammation correlated with
he risk of developing colorectal neoplasia. By contrast, in multi-
ariate analysis only histological inﬂammation was an important
eterminant of risk [30]. In the follow-up study, the multivariate
nalysis also showed that UC patients who had a macroscopically
ormal colon had a colorectal cancer risk similar to that of the
eneral population [31].
.5.  Ability of a drug to induce MH:  is it the only parameter to
mpact  the clinical course of IBD?
Three recent studies on endoscopic MH  have provided strong
vidence that the attainment of this end point leads to improved
linical outcomes [32–34]. The ﬁrst study, by Ardizzone et al. [32],
as a 5-year natural history study of 157 UC patients who were
art of a 25-year hospital-based inception cohort and treated with
heir ﬁrst course of corticosteroids. The authors used a modi-
ed Baron index to assess baseline endoscopic activity (with MH
eﬁned as a score of 0) and reported that a lack of MH  at 3 months
fter commencement of the ﬁrst course of corticosteroids was  the
nly variable associated with an increased risk of use of immuno-
uppressive therapy, hospitalization, and colectomy at 5 years of
ollow-up at multivariate analysis.
.6. Altogether, corticosteroids in IBD appear incapable of
aintaining clinical remission and, even more, to maintain MH
The  second study, a combined analysis of ACT 1 and 2, as well
s the ACT 2 extension study by Colombel et al. [33], addressed
he impact of the degree of endoscopic MH at week 8, as deﬁned
y the Mayo endoscopic sub-score, on a variety of future clinical
utcomes among both inﬂiximab-treated (n = 484) and placebo-
reated (n = 244) patients. For the end point of time to colectomy,
nﬂiximab-treated patients with lower endoscopy sub-scores at
eek 8 were more likely to be colectomy-free by week 54 (95% for
 score of 0, 95% for 1, 87% for 2, and 80% for 3; p = 0.004); however,r Disease 45 (2013) 986– 991
this  trend was not observed in placebo-treated patients. For symp-
tomatic remission at week 30 or 54, there was  a clear and highly
signiﬁcant separation between all 4 strata of endoscopic sub-scores
among both inﬂiximab-treated and placebo-treated patients, with
lower endoscopic sub-scores leading to higher rates of symp-
tomatic remission [week 30: inﬂiximab-treated patients (71% for
0, 51% for 1, 23% for 2, 10% for 3) and placebo-treated patients (55%
for 0, 38% for 1, 15% for 2, 6% for 3); week 54: inﬂiximab-treated
patients (73% for 0, 47% for 1, 24% for 2, 10% for 3) and placebo-
treated patients (67% for 0, 39% for 1, 9% for 2, 4% for 3); p < 0.0001
for all analyses]. Similar results with a highly signiﬁcant separa-
tion between all 4 strata of endoscopic sub-scores among both
inﬂiximab-treated and placebo-treated patients were observed for
the outcomes of corticosteroid-free remission, corticosteroid-free
symptomatic remission, median corticosteroid dose at week 30 or
54, MH  at week 30, and sustained MH  at weeks 30 and 54. Inter-
estingly, although these analyses restricted to inﬂiximab-treated
patients who achieved a clinical response at week 8 yielded similar
trends in terms of outcomes, restricting the analyses to inﬂiximab-
treated patients who achieved clinical remission at week 8 revealed
no difference in the outcomes between patients with an endoscopic
sub-score of 0 or 1.
The  third study, by Meucci et al. [34], followed 61 patients who
achieved clinical remission after 6 weeks of combined oral and rec-
tal mesalazine therapy for up to 1 year and deﬁned MH as a Mayo
endoscopic sub-score of r1. The authors observed rates of clinical
relapse at 1 year of 80% versus 23% in patients without and with
MH. Furthermore, MH  was the only independent predictor of clin-
ical relapse. It is worth noting that in this study the 1-year clinical
relapse rates were similar for patients with endoscopic sub-scores
of 0 or 1.
As  underscored by the authors of the studies here mentioned,
the simple description of the ability of a drug to induce MH  is not
the only parameter to impact the clinical course of the patient’s
disease and of the various forms of disease to be managed. The
fact is that no controlled studies are available on the outcome
of different therapeutic strategies based on clinical versus endo-
scopic parameters. In particular, for example, the achievement of
early endoscopic response to corticosteroids can be used to pre-
dict the risk of negative clinical outcomes, such as hospitalizations,
immunosuppressor use, and even colectomy; it also may  suggest
routine monitoring of endoscopic response after the end of treat-
ment for active disease and early introduction of more aggressive
treatments, such as immunosuppressors, in those patients who
do not achieve MH,  although this approach requires validation in
prospective trials.
3.7.  Endoscopic assessment of MH:  a helpful tool to guide
therapeutic decision-making?
It  is certainly useful to consider the endoscopic assessment of
MH to guide therapeutic decision-making, especially before start-
ing, altering the dose, switching or stopping expensive anti-TNF
therapy. In this context, a cross-sectional cohort study was per-
formed to assess the frequency and determinants of management
change in all children who  underwent endoscopy for the surveil-
lance or evaluation of established IBD. The study showed that
patients with mucosal injury were more likely to have a manage-
ment change than those with MH  (80% vs. 20%; p < 0.001), while
blood work and patient’s symptoms before the procedure did not
predict management outcome [35].
More recently, the STORI trial, mentioned above, focused on
the (endoscopically-guided) decision making in stopping anti-
TNF therapies. This prospective study was  performed to assess
the risk of relapse after inﬂiximab therapy was  discontinued in
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t multivariate analysis, risk factors for relapse included male sex,
he absence of surgical resection, leucocyte counts >6.0 × 10(9)/L,
evels of haemoglobin ≤145 g/L, CRP ≥5.0 mg/L, and faecal cal-
rotectin ≥300 g/g. Patients with no more than 2 of these risk
actors (approximately 29% of the study population) had a 15%
isk of relapse within 1 year. In this context, the same multivari-
te analysis showed that endoscopic MH,  assessed through CDEIS
=0), identiﬁed a subgroup of patients in whom, when combined
ith a low CRP, normal haemoglobin and clinical history, endo-
copic MH  could predict sustained remission in about 80% of them
25,26].
Finally, the endoscopic evaluation is already commonly per-
ormed within a year of ileocolic resection and recommended by
ome guidelines to guide prophylaxis in the setting of the postsur-
ical recurrence of CD [36].
Some studies pointed out that the severity of the endoscopic
esions at the start is more relevant than MH in affecting the clinical
mplications of the end points. In fact, a recent phase IIIB, multi-
entre, open-label clinical trial, performed to evaluate the efﬁcacy
f certolizumab pegol in improving endoscopic lesions in patients
ith active ileocolonic CD, showed that the rate of complete MH
as relatively low (8% at week 54), because of the severity of the
ntestinal lesions at baseline (more than 90% of patients having
eep ulcerations) [37].
Furthermore,  it is important to consider that patients under-
tandably dislike invasive procedures such as endoscopic proce-
ures. At present, the assessment of MH  represents a target difﬁcult
o be reached, which either way provides better support for a ther-
peutic decision than does clinical judgement alone.
.8.  Advanced endoscopic imaging to assess MH
Considering the importance of endoscopy in assessing MH  in
rder to assist therapeutic decision-making, it becomes obvious
hat there is a need for new and more advanced endoscopic
maging techniques for better characterization of mucosal inﬂam-
ation.
With regard to the screening for colorectal cancer, pancolonic
hromoendoscopy and targeted biopsies of suspicious lesions rep-
esent already a more effective surveillance method in IBD than
aking only multiple non-targeted biopsies; similarly, magniﬁca-
ion chromoendoscopy improves the detection of pre-neoplastic
nd neoplastic mucosal changes [38].
On the other hand, in the context of the assessment of mucosal
nﬂammation, magniﬁcation endoscopy has the potential to predict
elapse in patients with quiescent disease [39]. Furthermore, dye-
ess chromoendoscopy offers the potential to replace conventional
ye-based chromoendoscopy for lesion detection and assessment
f disease severity in IBD: i-scan signiﬁcantly improves the diagno-
is of severity and extent of mucosal inﬂammation in patients with
BD [40].
Confocal laser endoscopy can also detect more neoplasms in
urveillance colonoscopy of patients with IBD and can predict
eoplastic changes with high accuracy; furthermore, it has been
emonstrated that confocal laser endoscopy can reliably predict
nﬂammatory activity in IBD during ongoing endoscopy, even in
atients with macroscopically uneventful mucosa [41,42]. Endo-
ytoscopy harbours the potential to accurately determine various
nﬂammatory mucosal cells during ongoing endoscopy in IBD and
hus the severity of the inﬂammation [43].
These emerging imaging modalities enable the endoscopist to
etect and characterize more pre-neoplastic and neoplastic lesions
nd to predict mucosal inﬂammation more precisely as compared
o conventional white-light endoscopy, thus opening new avenues
or diagnostic and therapeutic strategies in IBD.r Disease 45 (2013) 986– 991 989
4. Future perspectives: from mucosal healing to deep
remission
4.1.  The new concept of “deep remission”
A new therapeutic target that is emerging in the scientiﬁc com-
munity is the concept of deep remission, which has already been
deﬁned as the combination of clinical remission (CDAI < 150) in the
absence of the residual use of steroids, along with more objective
variables, such as negativity of the indexes of biological activity of
the disease (CRP), and in association with MH.
While deep remission is an emerging concept in IBD, in rheuma-
toid arthritis, treatment goals no longer include symptom control
alone but also alteration of the biological processes underly-
ing synovial inﬂammation and progressive structural destruction,
thereby preventing structural joint damage and functional decline
[44]. Achieving deep remission (clinical remission and MH)  might
be the only way to alter the course of the disease in IBD patients.
4.2.  Deep remission and Crohn’s Disease
From the EXTEND study, post hoc data about deep remission
in CD, deﬁned here as clinical remission (CDAI > 150) together with
MH,  can be derived. Deep remission at 1 year was  signiﬁcantly more
common in patients treated continuously with adalimumab than
in those treated with placebo, although only recorded in 19.4% of
patients. Quantifying the magnitude of the difference at 1 year cor-
responds to an OR of 30.4; in the third month, however, there is a
carry-over effect of induction, so that even in the arm maintaining
placebo 9.8% patients meet the criteria for deep remission [28]. In
EXTEND, patients achieving deep remission at week 12 had reduced
rates of hospitalization, fewer dose escalations, better quality of life
and improved work productivity and activity [45].
Therapeutic interventions in the past, considering those pro-
vided in the pivotal trials for approval of biologic drugs, were aimed
at the advanced stages of CD. In this context the possibility of a
striking impact on long-term disability is reduced, because com-
plications and disability in advanced diseases are in fact already
present, and even the most effective drug is likely to have little
effect and little capacity to change the clinical course of the dis-
ease. Recent evidence suggests that when therapeutic intervention
occurs early in the disease, it is more likely that the disease can be
treated positively [46].
On the other hand, the selection of patients and treatment is
ﬂexible and should always take into account the history and total
weight of disease, in the light of a perspective which includes the
following: considerations of the risk/beneﬁt ratio, preference and
expectations of the patient, and the ratio between these elements
and the severity and complexity of the disease.
The top-down strategy, evaluated in the “step-up/top-down”
trial,  has proven to be more effective than the step-up strategy
in inducing and maintaining remission in steroid-free patients 1
and 2 years after enrolment. In this study, 2 years after randomiza-
tion, complete MH  was  observed in 73% of patients in the top-down
group compared with only 30% of those in the step-up group [47].
Similarly, major effectiveness in the early phases of the disease
(as identiﬁed in the subgroups with shorter duration of disease
at diagnosis) has been demonstrated by post hoc analysis of the
CHARM study, including adalimumab. In fact, in this study, patients
with duration of disease of less than 2 years presented a remis-
sion rate of 51% in the treatment arm vs. 17% in the placebo arm
(p = 0.014), while in patients with a disease duration between 2
and 5 years the remission rate was  44% in the treatment arm vs.
11% in the placebo arm. Finally, in patients with disease duration of
more than 5 years the remission rate was 35% in the treatment arm
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espite the small numbers and the evaluation of a more difﬁcult
arget to achieve than MH,  in post hoc analysis of the EXTEND trial
ith adalimumab. In this study the reduction of risk of relapse com-
ared to placebo is lost for groups with longer duration of disease
nd the results are strongest for diseases of less than 2 years.
In  this study, the MH  rate was 44% in the group with duration of
isease of less than 2 years, 40% in the group with disease duration
etween 2 and 5 years, and 21% in the group with disease duration
reater than 5 years [48]. Also regarding deep remission, another
ost hoc analysis of the EXTEND study shows a trend towards a
igniﬁcant reduction in frequency, going from the group of subjects
ith disease duration of less than 2 years (deep remission in 33%
f patients) to those with over 5 years of disease duration (deep
emission in 16% of patients) [20].
.3. The “Lèmann Score”
CD  may  have an extremely variable course, and therefore an
nstrument to measure cumulative structural damage, predicting
ong-term disability, is needed. Beaugerie et al. in 2006 identiﬁed
rognostic factors associated with a more disabling course of dis-
ase [49]. Recently, IPNIC [50] developed a score, called “Lèmann
core”, which should take into account damage location, severity,
xtent, progression and reversibility, as measured by diagnostic
maging techniques and history of surgical resection. This score is
xpected to be able to portray a patient’s disease course on a double
xis graph, with time as the x-axis, bowel damage severity as the
-axis, and the slope of the line connecting data points as a mea-
ure of disease progression. This instrument could be used to assess
he effect of various medical therapies on the progression of bowel
amage, i.e. using accelerated step care in the case of severe CD.
Sustained deep remission is an important goal for improving
utcomes in this chronic, progressive disease, and it is an achievable
oal in today’s clinical practice. We  can already tailor our approach
o each patient, for optimum, individualized management. In the
ear future, we will be further guided by new treatment strategies
nd indices of prognosis and damage.
.4. Deep remission and ulcerative colitis
With regard to UC, MH  is also an important predictor of long-
erm as well as of short-term outcomes. Sandborn et al. [51]
emonstrated that inﬂiximab-treated patients with endoscopic
cores of 2 or 3 at week 8 were signiﬁcantly more likely to progress
o colectomy at week 54. Colectomy-free probability at week 54
as 95%, 95% and 80% in patients with week 8 endoscopic scores
f 0–1, 2, and 3, respectively. These ﬁndings are supported by the
revious work by Froslie et al. [15], in which patients with MH  at 1
ear were less likely to undergo colectomy during the subsequent
-year follow-up period.
The  achievement of deep remission might be the only way to
lter the course of IBD. However, there is no validated deﬁnition of
eep remission in IBD, even though an attempt was made recently
or CD. In UC, deep remission could be deﬁned as clinical remis-
ion associated with complete MH.  In the near future, the concept
f deep remission may  evolve, with the inclusion of histological
emission in UC and transmural healing in CD. However, the ability
f the available drugs to induce and maintain deep remission in IBD
eeds to be assessed in large disease-modiﬁcation trials.
.  ConclusionIt  is becoming clear that treatment for clinical remission alone
ay not be an adequate approach for IBD in the long term. There
s a growing body of evidence that the attainment of MH in IBD is
uspicious, as it leads to a number of improved clinical outcomes.
[r Disease 45 (2013) 986– 991
MH,  which is a new concept concerning the goal of deep remission,
and rarely achieved with traditional drugs, can now be achieved and
maintained by means of biological drugs. Current evidence suggests
that the achievement of MH  might signiﬁcantly change the course
of the natural history of IBD and should represent an objective end
point of future therapeutic trials, particularly for colonic diseases.
However,  until future prospective studies identify and validate a
single gold standard MH  scoring system (separately for CD and UC)
that is relatively easy to use and predictive of clinical outcomes,
establishing a critical time point for measuring MH,  and demon-
strating that treatment to MH  can change the natural history of
these diseases, MH  will remain an admirable secondary goal in the
treatment of IBD patients.
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